Patrick Machado

Mr Machado has served as a member of our Board since November 2020. Mr Machado cofounded and served as Chief Financial Officer and Chief Business Officer at Medivation, Inc. until his retirement in 2014 and served as a member of Medivation’s Board of Directors from 2014 until its acquisition for approximately $14 billion by Pfizer in 2016. During his tenure at Medivation, Mr Machado helped lead the company through substantial growth and challenges, providing strong leadership during the clinical development and successful commercial launch of XTANDI®. Mr Machado serves as Chair of the Board of Directors of the publicly traded biotechnology company Adverum Biotechnologies, Inc. and as a member of the Boards of Directors of Alumis, Inc. and Arcus Biosciences, Inc. Mr Machado previously served on the Boards of the publicly traded biotechnology companies Principia Biopharma Inc., Roivant Sciences Ltd., Turning Point Therapeutics, Inc., Turnstone Biologics Corp., Chimerix, Inc., and Acelyrin, Inc. Earlier in his career, from 1998 to 2001, Mr Machado worked with ProDuct Health, Inc., a medical device company, as Senior Vice President, Chief Financial Officer, and earlier, as General Counsel. He served as a consultant to Cytyc to assist with transitional matters from 2001 to 2002. Mr Machado worked for Morrison & Foerster LLP, a leading international law firm, and for the Massachusetts Supreme Judicial Court. Mr Machado received his JD degree from Harvard Law School and holds both a BS degree in economics and a BA degree in German from Santa Clara University in California.